PTC Therapeutics Initiates Second Phase 3 Trial of Ataluren in Nonsense Mutation Cystic Fibrosis
In an effort to alleviate symptoms in patients with nonsense mutation cystic fibrosis–a severe form that leads to little if any CFTR protein production–PTC Therapeutics, Inc. is initiating a global confirmatory Phase 3 clinical trial to test Translarna (ataluren) under the trial name ACT CF. In a previous,…